ETFs Genome & Company

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. 2026-10-15			5-day change	1st Jan Change
4,220.00 ^KRW	-11.16%		-22.85%	-38.66%

09-20	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	CI
08-14	Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

ETFs positioned on Genome & Company

Name		YTD change	Weight	AuM
DIMENSIONAL EMERGING MARKETS CORE EQUITY 2 ETF - USD		+16.26%	-	9,273 M€

Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company